Tophof MA, et al. - The subcutaneous immunotherapy (SCIT)-related incidence of local and systemic side effects in pediatric patients was determined via a non-interventional prospective observing longitudinal study including 18 study centers, recording 8,640 treatments and 10,015 injections. Safety of subcutaneous immunotherapy was shown in pediatric patients. Compared with adult patients, pediatric patients had similar rates of local side effects and low rates of severe systemic side effects. However, more often than expected occurrence of local and systemic reactions observed later than 30 minutes after injection called for attention on behalf of pediatricians, patients, and parents.